Non-motor symptoms of Parkinson’s disease

Carroll, V. Susan; Rossiter, Rachel; Blanchard, Denise

doi:10.31128/ajgp-07-21-6093

Cited by 8 publications

(14 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Focusing only on motor symptoms and ignoring NMS may not reflect the patient's experience of living with PD [14]. Non-motor symptoms negatively impact the quality of life of PD patients and add to their disease burden and disability [15].…”

Section: Open Accessmentioning

confidence: 99%

Screening for non-motor symptoms in Egyptian patients with Parkinson’s disease

Shaheen

Ali

Farghaly

et al. 2022

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

Background Most of the patients with Parkinson’s disease (PD) suffer from non-motor symptoms (NMS). Despite their marked effect on patients’ quality of life, NMS remain under-estimated by physicians, patients and caregivers. The aim of this study was to suggest a battery to screen for the presence of NMS in PD patients in the setting of an outpatient clinic and to assess the NMS of PD in Egyptian patients and factors affecting them. Results This study was conducted on 50 patients with PD, 35 males (70%) and 15 females (30%) whom their age ranged from 36 to 80 years with a mean of 62.88 ± 8.74 years. All patients were assessed using the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS), Apathy Scale (AS), Montreal Cognitive Assessment (MOCA), Hamilton Depression Rating Scale (HDRS) and Parkinson’s Disease Sleep Scale (PDSS). The mean age at disease onset was 59.10 ± 9.34 years and the mean disease duration was 3.76 ± 3.16 years. 98% of patients (49 out of 50) had at least one non-motor symptom. The mean MDS-UPDRS scores were 15.74 ± 7.93 for part I, 17.94 ± 11.61 for part II and 42.32 ± 22.74 for part III. The mean score for AS was 9.90 ± 10.66 with 70% of patients considered apathetic. The mean MOCA score was 21.12 ± 4.73 with 38 patients (76%) found to be cognitively impaired. The mean HDRS score was 12.26 ± 8.52 with 34 patients (68%) found to be depressed. The mean PDSS score was 92.22 ± 32.53 with sleep disturbances found in 38 patients (76%). A statistically significant negative correlation was found between the HDRS and PDSS scores (P value < 0.001). Age of patients, age at disease onset and disease duration were not correlated to MDS-UPDRS, AS, MOCA, HDRS and PDSS scores. Conclusions Most of the patients with PD were found to suffer from NMS including apathy, cognitive impairment, depression and sleep disturbances. Physicians need to screen their PD patients for NMS on regular basis using the appropriate tools. Self-administered questionnaires could function as reliable screening tools for NMS in PD patients.

show abstract

Section: Open Accessmentioning

confidence: 99%

Screening for non-motor symptoms in Egyptian patients with Parkinson’s disease

Shaheen

Ali

Farghaly

et al. 2022

Egypt J Neurol Psychiatry Neurosurg

View full text Add to dashboard Cite

show abstract

“…These abnormally folded proteins then aggregate with each other forming Lewy body lesions with pathology beginning in the brain stem, progressing via the olfactory tract, and spreading via vagus nerve pathways towards the mid brain and eventually out towards the cerebral cortex 4,5,9 . This type of spread may not occur for all PD cases; however, the gradual degeneration of susceptible neurons via this pathway has led us to understand that neurodegeneration in PD occurs from a complex interplay between genetic and environmental factors with pathology beginning long before the onset of motor symptoms 2,4,5,10,11 …”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

“…Rather, PD progresses through an early asymptomatic stage, non‐motor symptoms becoming evident in the prodromal disease stage, and motor symptoms appearing only later in the evolution of the disease 5,9–11 . Disease symptoms within the prodromal stage are often subtle, affecting autonomic nervous system, sleep, and olfactory functioning 4,5,10,11 . Symptoms include loss of smell, gastrointestinal disturbances (i.e., constipation), rapid eye movement sleep disorder, urinary dysfunction, orthostatic hypotension, and depression 5,6,10,11 .…”

Section: Introductionmentioning

confidence: 99%

“…The problem in PD is that early disease signs are often attributed to normal ageing leading to misdiagnosis of symptoms, until the late motor symptoms are evident 6 . This means that the spread of PD can go undetected for many years before motor symptoms become apparent 4,5,10,11 . As PD progresses and symptoms manifest and worsen, physical and psychological functioning becomes impaired, decreasing personal independence, resulting in varied levels of disability and dependency, and impacting overall quality of life 4–6 …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Exploring Parkinson's disease prevalence in regional, rural and remote Australia: A systematic scoping review

Fealy,

Logan,

Micalos

et al. 2023

Australian J Rural Health

Self Cite

View full text Add to dashboard Cite

IntroductionIdiopathic Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder worldwide. Due to ageing populations, prevalence estimates for PD are set to increase in western countries including Australia.ObjectiveThis study aims to investigate the prevalence of PD in regional, rural and remote areas of Australia, to inform the provision of equitable PD‐specific care.DesignA scoping review, following the Joanna Briggs Institute methodology for scoping reviews and the Preferred Reporting Items for Systematic reviews and Meta‐Analyses extension for Scoping Reviews (PRISMA‐ScR), was conducted. An electronic search of four databases and the search engine google scholar was completed in May 2022 and updated in September 2023. Article screening and quality appraisal were undertaken independently by at least two reviewers.FindingsOf 514 records screened, six articles (between 1966 and 2019) were identified and included for review. Wide variations in PD prevalence were evident, ranging from 0.58 to 8.5 per 1000 people. Two studies suggested prevalence may be higher in regional, rural and remote areas of Australia than in urban localities.DiscussionThe limited number of studies identified, and wide variation in prevalence rates makes it difficult to draw firm conclusions to inform heath care planning and resource allocation.ConclusionA paucity of reliable prevalence data indicates the need for well‐designed, country‐specific epidemiological studies to be conducted to estimate the actual impacts of the disease to inform public health planning, particularly in regional, rural and remote areas where access to PD‐specific care is already inequitable.

show abstract